HK1214968A1 - 用於非酒精性脂肪肝病(nafld)的新组合物 - Google Patents

用於非酒精性脂肪肝病(nafld)的新组合物 Download PDF

Info

Publication number
HK1214968A1
HK1214968A1 HK16103017.5A HK16103017A HK1214968A1 HK 1214968 A1 HK1214968 A1 HK 1214968A1 HK 16103017 A HK16103017 A HK 16103017A HK 1214968 A1 HK1214968 A1 HK 1214968A1
Authority
HK
Hong Kong
Prior art keywords
fatty liver
nafld
liver disease
nonalcoholic fatty
novel composition
Prior art date
Application number
HK16103017.5A
Other languages
English (en)
Chinese (zh)
Inventor
Pankaj Patel
Rajendrakumar HARIPRASAD JANI
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Publication of HK1214968A1 publication Critical patent/HK1214968A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK16103017.5A 2013-04-22 2013-06-25 用於非酒精性脂肪肝病(nafld)的新组合物 HK1214968A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1468/MUM/2013 2013-04-22
IN1468MU2013 IN2013MU01468A (cg-RX-API-DMAC10.html) 2013-04-22 2013-06-25
PCT/IN2013/000391 WO2014174524A1 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)

Publications (1)

Publication Number Publication Date
HK1214968A1 true HK1214968A1 (zh) 2016-08-12

Family

ID=49253372

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103017.5A HK1214968A1 (zh) 2013-04-22 2013-06-25 用於非酒精性脂肪肝病(nafld)的新组合物

Country Status (21)

Country Link
US (3) US20160166539A1 (cg-RX-API-DMAC10.html)
EP (1) EP2988736A1 (cg-RX-API-DMAC10.html)
JP (1) JP6246895B2 (cg-RX-API-DMAC10.html)
KR (1) KR101617812B1 (cg-RX-API-DMAC10.html)
CN (1) CN105377246B (cg-RX-API-DMAC10.html)
AP (1) AP2015008674A0 (cg-RX-API-DMAC10.html)
AU (1) AU2013387996B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015020600A2 (cg-RX-API-DMAC10.html)
CA (1) CA2900435C (cg-RX-API-DMAC10.html)
EA (1) EA201592020A1 (cg-RX-API-DMAC10.html)
GE (1) GEP201706663B (cg-RX-API-DMAC10.html)
HK (1) HK1214968A1 (cg-RX-API-DMAC10.html)
IL (2) IL240183A (cg-RX-API-DMAC10.html)
IN (1) IN2013MU01468A (cg-RX-API-DMAC10.html)
MA (1) MA38385A1 (cg-RX-API-DMAC10.html)
MX (1) MX346943B (cg-RX-API-DMAC10.html)
MY (1) MY180160A (cg-RX-API-DMAC10.html)
PH (1) PH12015501795A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201506218UA (cg-RX-API-DMAC10.html)
UA (1) UA114360C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014174524A1 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009136A1 (en) 2011-01-31 2016-04-20 Cadila Healthcare Limited Treatment for lipodystrophy
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
UA114360C2 (uk) 2013-04-22 2017-05-25 Каділа Хелткере Лімітед Спосіб лікування та/або зменшення інтенсивності неалкогольної жирової хвороби печінки (нжхп)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (cg-RX-API-DMAC10.html) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (cg-RX-API-DMAC10.html) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
CN109069503A (zh) * 2016-04-22 2018-12-21 景凯生物科技股份有限公司 纳美芬(nalmefene)、纳曲酮(naltrexone)或其衍生物在治疗(非)酒精性脂肪肝炎(nash)或非酒精性脂肪性肝病(nafld)的应用
EP3551180B1 (en) * 2016-12-09 2021-09-29 Cadila Healthcare Limited Treatment for primary biliary cholangitis
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
CN111182904A (zh) * 2017-10-06 2020-05-19 吉利德科学公司 包含acc抑制剂的组合治疗
CN109675016A (zh) * 2017-10-18 2019-04-26 上海贺普药业股份有限公司 非酒精性脂肪性肝病的治疗药物
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用
US12201609B2 (en) * 2018-12-18 2025-01-21 Zydus Lifesciences Limited Saroglitazar for the treatment of hepatocellular carcinoma
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
WO2022128870A1 (en) * 2020-12-18 2022-06-23 Société des Produits Nestlé S.A. Compositions and methods using at least one glycine or derivative thereof and/or at least one n-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol
US20220378786A1 (en) * 2021-05-21 2022-12-01 HepQuant, LLC Methods of defining functional change and slowing progression in chronic liver disease
WO2025238663A1 (en) * 2024-05-16 2025-11-20 Zydus Lifesciences Limited Saroglitazar for the treatment of alcoholic liver diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
SK695A3 (en) 1992-07-03 1995-07-11 Smithkline Beecham Plc Heterocyclic compounds method of their production and using
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
US6075140A (en) 1995-04-28 2000-06-13 Daiichi Pharmaceutical Co., Ltd. Pentacyclic compound
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
EP1124807A1 (en) 1997-10-27 2001-08-22 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
CN1208326C (zh) 1998-04-23 2005-06-29 雷迪实验室有限公司 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物
JP2002507543A (ja) 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション 二環系化合物、その製造方法およびそれらを含有する薬学的組成物
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
ES2449194T3 (es) 2000-01-19 2014-03-18 Cadila Healthcare Limited Compuestos que tienen actividades hipolipidémica e hipocolesterolémica, procedimiento para su preparación y composiciones farmacéuticas que los contienen
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4261546B2 (ja) 2003-09-26 2009-04-30 三菱レイヨン株式会社 電気泳動装置および電気泳動法
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
EP2096170B1 (en) * 2005-09-19 2011-08-10 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
WO2008036638A2 (en) * 2006-09-18 2008-03-27 Alnylam Pharmaceuticals, Inc. Rnai modulation of scap and therapeutic uses thereof
JP2008184429A (ja) * 2007-01-30 2008-08-14 Japan Health Science Foundation 肝臓トリグリセリド濃度低下剤
ES2441665T3 (es) 2009-11-26 2014-02-05 Genfit Utilización de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos
MX2013004123A (es) 2010-10-12 2013-12-16 Univ Johns Hopkins Composiciones antitusigenas que comprenden memantina.
EP3009136A1 (en) * 2011-01-31 2016-04-20 Cadila Healthcare Limited Treatment for lipodystrophy
UA114360C2 (uk) 2013-04-22 2017-05-25 Каділа Хелткере Лімітед Спосіб лікування та/або зменшення інтенсивності неалкогольної жирової хвороби печінки (нжхп)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (cg-RX-API-DMAC10.html) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9951009B2 (en) 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (cg-RX-API-DMAC10.html) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
JP2016515608A (ja) 2016-05-30
IL247231A (en) 2017-03-30
MX346943B (es) 2017-04-06
JP6246895B2 (ja) 2017-12-13
EA201592020A1 (ru) 2016-05-31
WO2014174524A1 (en) 2014-10-30
AU2013387996B2 (en) 2015-12-10
US20160166539A1 (en) 2016-06-16
UA114360C2 (uk) 2017-05-25
IL240183A (en) 2016-08-31
BR112015020600A2 (pt) 2017-07-18
IL240183A0 (en) 2015-09-24
AU2013387996A1 (en) 2015-09-24
PH12015501795A1 (en) 2015-11-09
GEP201706663B (en) 2017-05-10
US20180185330A1 (en) 2018-07-05
US20170087127A1 (en) 2017-03-30
CN105377246A (zh) 2016-03-02
CA2900435C (en) 2017-02-14
KR101617812B1 (ko) 2016-05-03
US9814697B2 (en) 2017-11-14
MA38385A1 (fr) 2017-09-29
AP2015008674A0 (en) 2015-08-31
EP2988736A1 (en) 2016-03-02
WO2014174524A8 (en) 2015-10-01
CA2900435A1 (en) 2014-10-30
MX2015010769A (es) 2015-11-26
SG11201506218UA (en) 2015-09-29
KR20150118990A (ko) 2015-10-23
CN105377246B (zh) 2018-03-20
IN2013MU01468A (cg-RX-API-DMAC10.html) 2015-04-17
MY180160A (en) 2020-11-23

Similar Documents

Publication Publication Date Title
WO2014174524A8 (en) A novel composition for nonalcoholic fatty liver disease (nafld)
MX360979B (es) Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
PH12015502136A1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
MY178621A (en) Deuterated cftr potentiators
WO2012087976A3 (en) Novel inhibitors of hepatitis c virus replication
MX349159B (es) Derivados deuterados de ivacaftor.
NZ739248A (en) Inhibitors of hepatitis c virus
MX2019005082A (es) Composiciones que comprenden 15-ohepa y metodos para usar las mismas.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
MX2012003171A (es) Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
IN2014MN02082A (cg-RX-API-DMAC10.html)
WO2009134616A8 (en) Novel inhibitors of hepatitis c virus replication
EA201491500A1 (ru) Способы лечения фиброза
BR112016024020A2 (pt) composição farmacêutica
IN2014CN00572A (cg-RX-API-DMAC10.html)
WO2011075822A8 (en) Immunogenic compositions and related methods
MX2012012095A (es) Analogos de tiazolidinadiona.
EP3037093A4 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating chronic obstructive pulmonary diseases
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
BR112015022571A2 (pt) método de tratamento de esteatose hepática
NZ707773A (en) Methods of treating liver diseases
MX2013011561A (es) Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.